Who is sponsoring NCT06256926?

NCT06256926 is sponsored by COD Research Private Ltd.

What condition does NCT06256926 study?

NCT06256926 studies Fatty Liver Without Mention of Alcohol.

Is NCT06256926 still recruiting?

NCT06256926 is currently completed. Last updated 13 February 2024.

Last reviewed 2024-02-13 · How we verify

NCT06256926: NAFLD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study of Curcuvail® in Patients With Non-alcoholic Fatty Liver Disease

Completed Phase 2 Last updated 13 February 2024

What this trial tests

Phase 2 trial testing Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids) in Fatty Liver Without Mention of Alcohol in 30 participants. Completed in 25 November 2021.

Timeline

8 January 2021

Primary endpoint
25 November 2021

25 November 2021

Quick facts

Lead sponsor	COD Research Private Ltd
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	8 January 2021
Primary completion	25 November 2021
Estimated completion	25 November 2021
Sites	1 location across India

Drugs / interventions tested

Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids) — full drug profile →
Placebo product

Conditions studied

Fatty Liver Without Mention of Alcohol — all drugs for Fatty Liver Without Mention of Alcohol →

Sponsor

COD Research Private Ltd — full company profile →

Who can join

Adults 18 to 70, any sex, with Fatty Liver Without Mention of Alcohol. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It comprises a wide spectrum of disorders that range from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, related cirrhosis, and even hepatocellular carcinoma (HCC).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.
Khare T, Liu K, Chilambe LO, Khare S. · · 2025 · cited 12× · PMID 39796162 · DOI 10.3390/ijms26010306
Novel Pharmacological and Nanotechnology-Based Therapeutic Strategies for MASLD.
Villaseñor-Tapia EC, Franco-Acevedo A, Rosas-Campos R, Armendariz-Borunda J. · · 2026 · PMID 42198278 · DOI 10.3390/pharmaceutics18050584

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06256926 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by COD Research Private Ltd
Last refreshed: 13 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06256926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing